EANS-Adhoc: Sartorius AG / Sartorius plans to acquire liquid handling business from Biohit

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

26.10.2011

Acquisition enables substantial expansion of the Lab Instruments
portfolio| Purchase price totals EUR68 million | Acquisition expected
to be accretive to relevant net profit already in 2012

Sartorius AG, a leading international process and laboratory
technology provider, today signed an agreement to acquire the entire
liquid handling business of Helsinki-based Biohit Oyj (NASDAQ OMX:
BIOBV) through its 100% subsidiary Sartorius Lab Holding GmbH. The
purchase price amounts to EUR68 million. This transaction, which is
subject to clearance by antitrust authorities and to approval by the
General Meeting of Biohit Oyj, is expected to close in December of
2011.

The liquid handling business of the Finnish company Biohit generated
net sales of approx. EUR38 million and an EBITDA margin of approx.
13% in fiscal 2010. Its product range includes mechanical and
electronic pipettes, as well as the associated consumables, which are
used in research, quality assurance and academic laboratories as well
as hospitals.

The business to be acquired represents an ideal fit with Sartorius
AG´s portfolio in its Laboratory Instruments area, which includes
precision lab balances, laboratory water purification systems and
moisture analyzers, among other products. By expanding its product
offering, Sartorius AG will be enhancing its position with end
customers and distributors, and expects significant growth through
the combination and extension of its sales activities.

Subject to the transaction are all assets of the liquid handling
segment of Biohit, including production facilities in Finland and
China, as well as sales subsidiaries in several countries.

The acquisition will be financed from an existing credit facility,
and is projected to be accretive to relevant net profit (earnings
adjusted for extraordinary items and non-cash amortization) for the
Sartorius Group already in 2012. Sartorius expects to incur
transaction-related expenses of around EUR2 million. The company´s
sales and profit guidance for the full year of 2011 will remain
unaffected by the acquisition.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of the
Sartorius Group, will discuss the transaction with analysts and
investors on Thursday, October 27, 2011, at 3:00 p.m. Central
European Time in a webcast teleconference. You may dial into the
teleconference starting at 2:45 p.m. CET at the following numbers:
Germany +49 (0)69 2222 10632; France +33 (0)1 70 48 01 63; UK +44
(0)20 7660 0009; USA +1 646 254 3371. The dial-in code is as follows:
7741122 The webcast and presentation can be viewed at
www.sartorius.com.

Goettingen, October 26,2011

Further inquiry note:
Andreas Theisen
Tel.: +49 (0) 551 308 1668
E-Mail: Andreas.Theisen@sartorius.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Sartorius AG
Weender Landstr. 94-108
D-37075 Göttingen
phone: +49 (0)551 308-0
FAX: +49 (0)551 308-3289
mail: info.investor@sartorius.com
WWW: http://www.sartorius.com
sector: Biotechnology
ISIN: DE0007165607, DE0007165631
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English